Omeros Turns Corner With Novo Deal, YARTEMLEA Launch

Omeros Corporation ((OMER)) has held its Q4 earnings call. Read on for the main highlights of the call.

Omeros Corporation’s latest earnings call struck an upbeat tone, driven by a landmark deal with Novo Nordisk and the U.S. launch of YARTEMLEA. Management highlighted a sharp swing to profitability, a stronger balance sheet and early commercial traction, while acknowledging remaining risks from convertible debt, noncash volatility and the still‑early stage of formulary adoption.

Transformative Novo Nordisk Deal Reshapes Balance Sheet

Omeros closed an asset purchase and license agreement with Novo Nordisk for zaltenibart, securing $240 million upfront and $100 million in near‑term milestones the company views as achievable. The package also includes up to $410 million in development and approval milestones and as much as $1.3 billion tied to sales, for potential total economics of up to $2.1 billion.

Retained Economics and Transition Support on Zaltenibart

Beyond the headline numbers, Omeros kept rights to MASP‑3 small‑molecule inhibitors and negotiated tiered royalties on zaltenibart that could reach the high teens. A transition services agreement ensures Novo reimburses Omeros for certain employee costs and inventories, effectively reducing near‑term cash burn as the asset moves under Novo’s operational control.

YARTEMLEA Wins FDA Approval in TA‑TMA

The FDA approved YARTEMLEA (narsoplimab) as the first and only treatment for transplant‑associated thrombotic microangiopathy in adults and children two years and older. The label is clean, with no boxed warning, no REMS program and no required vaccinations, eliminating barriers that often slow adoption for new hospital‑based therapies.

High‑Value Pricing and Utilization Profile

Commercial rollout began swiftly, with distributors fully supplied in January and initial sales following shortly thereafter. YARTEMLEA is priced at approximately $36,000 per vial, and with median use of eight to ten vials per treatment course in trials and expanded access, the implied drug cost per course runs in the roughly $288,000 to $360,000 range.

Early Launch Traction at Key Transplant Centers

Commercial efforts are concentrated on roughly 80 leading transplant centers that account for about 80% of U.S. stem cell transplants. Pharmacy and Therapeutics committee approvals have already been secured at half of the top 10 centers, 40% of the top 20, 35% of the top 40 and around 30% of the top 80 centers, signaling encouraging institutional uptake.

Payer Access Off to a Strong Start

On the reimbursement front, third‑party payers have so far approved 100% of pre‑authorization requests for YARTEMLEA. This early green light from insurers reduces a major commercial risk and should help speed time to treatment for critically ill patients, supporting both clinical adoption and revenue ramp potential.

Q4 Profitability Boosted by Deal Economics

For the fourth quarter of 2025, Omeros reported net income of $86.5 million, or $1.22 per share, reversing a $30.9 million net loss in the prior quarter. Results included a $237.6 million net gain tied to the zaltenibart transaction; excluding a sizable noncash derivative adjustment, non‑GAAP adjusted net income reached $222.5 million, or $3.14 per share.

Cash Position Strengthened and Debt Reduced

As of December 31, 2025, cash and investments stood at $171.8 million, up $135.7 million sequentially, largely reflecting upfront proceeds from Novo Nordisk. Omeros used part of the cash to retire a $67.1 million secured term loan and repay $17.1 million of 2026 convertible notes, leaving only $70.8 million in principal outstanding on unsecured 2029 convertible notes.

Commercial Infrastructure and Rapid Delivery Capability

To support the YARTEMLEA launch, Omeros has built logistics that can deliver drug within 24 hours of an order to both hospital and outpatient settings. The company has also deployed account managers, market access leads, medical science liaisons and reimbursement specialists to accelerate formulary reviews and prior‑authorization approvals.

Pipeline Advances Beyond Complement Franchise

Outside its complement programs, Omeros is advancing a PDE7 inhibitor (OMS527) for cocaine use disorder with funding from a U.S. research agency. The T‑CAT pathogen‑targeting platform has shown in vivo activity against multidrug‑resistant organisms, with patents filed and a scientific publication planned, while the OncotoX‑AML program is in IND‑enabling studies after demonstrating up to 99% reversible killing of myeloid progenitor cells in primate models.

Noncash Volatility from Convertible Note Derivative

Fourth‑quarter results included a $136 million noncash loss tied to the mark‑to‑market valuation of an embedded derivative in the 2029 convertible notes, driven by the stock price’s surge from $4.10 to $17.18 during the period. Management cautioned that similar derivative revaluations can inject substantial quarter‑to‑quarter swings into reported GAAP earnings, independent of underlying operations.

Formulary Penetration Still in Early Innings

While early adoption metrics are favorable, Omeros noted that formal coverage for YARTEMLEA remains incomplete, with only about 30% of the top 80 transplant centers having the drug on formulary. The company plans continued education and nonpersonal promotion across roughly 175 transplant centers nationwide to broaden access and convert clinical interest into routine use.

Reliance on Milestones and Future Commercial Upside

Management emphasized that part of the company’s near‑term liquidity and long‑term upside hinges on achieving undisclosed milestone triggers and future royalties from Novo Nordisk. While they expressed confidence in meeting the $100 million near‑term milestones and longer‑term hurdles, these payments are not guaranteed and introduce an element of execution risk.

Convertible Note Overhang Remains

Despite recent pay‑downs, Omeros still carries $70.8 million in principal on its 2029 convertible notes, which mature in June 2029. These securities include equity‑linked features that can influence future earnings via derivative accounting and may ultimately affect capital structure depending on share price performance and potential conversions.

Regulatory Speed Bump for OMS527

The OMS527 program encountered a regulatory delay when the FDA requested additional preclinical data before allowing the planned inpatient human study to proceed. Omeros is preparing for a meeting with the agency to address the questions, which pushes back the clinical start but does not appear to alter the strategic importance of the cocaine use disorder opportunity.

Rising Operating Costs Amid Launch Investment

Fourth‑quarter costs and expenses from continuing operations before interest totaled $29.1 million, up about 10% versus the prior quarter. Management signaled that sales and marketing expenses will rise further in early 2026 to support the YARTEMLEA launch, and the company is withholding near‑term revenue guidance while market access and physician adoption continue to build.

Guidance Signals Self‑Sustaining Franchise Ahead

Looking ahead, Omeros expects the YARTEMLEA program to become financially self‑sustaining in 2026 and projects company‑wide positive cash flow in 2027. For the first quarter of 2026, operating expenses should be similar to Q4 levels, with lower R&D due to reimbursed zaltenibart costs and higher sales and marketing, while noncash derivative swings on the 2029 notes will remain a prominent feature of reported results.

Omeros’s call painted a picture of a company transitioning from development stage to commercial execution, buoyed by a transformative partnership and a first‑in‑class approval. Investors will be watching the pace of YARTEMLEA uptake, milestone realization and management’s handling of derivative‑driven earnings volatility as key signposts for the next leg of the story.